Summary
The effects of trimazosin on blood pressure and cardiovascular homeostasis were studied in 12 subjects with untreated essential hypertension of mild or moderate degree. After a 3-day placebo period, the subjects were given trimazosin at the dose of 50, 100, or 200 mg twice daily (7 am and 7 pm) according to a randomized, double-blind crossover protocol. Each treatment was prolonged for 3 days and separated from the subsequent treatment by a 2-day placebo period. Blood pressure (sphygmomanometery) and heart rate were measured at rest during various laboratory maneuvers on the first and third day of the initial placebo, on the first and third day of the drug periods, and on the second day of the intervening placebo periods. Compared to placebo values, trimazosin caused a reduction in systolic and diastolic blood pressure which was well sustained through the time between the morning and the evening administration of the drug and was accompanied by only a slight tachycardia. The antihypertensive effect was similar in the supine and up-right position and in both instances it was greater for the 100 or 200 mg twice daily dose than for the 50-mg twice daily dose. The pressor and tachycardic responses to cold pressor test and to isometric and dynamic exercise were unaffected by the various doses of trimazosin whose antihypertensive effect was therefore similarly evident at rest and during behaviorally occurring blood pressure rises. Trimazosin also left unchanged the blood pressure and heart rate adjustments to passive tilting, its only effect being a modest and asymptomatic reduction in systolic blood pressure when tilting was performed during the first day of its administration at the highest dose. It is concluded that 100 mg or 200 mg twice daily of trimazosin effectively reduced high blood pressure. Both initially and at a later stage these doses did not modify the blood pressure adjustment to tilting, thereby preserving blood pressure homeostasis.
Similar content being viewed by others
References
de Leeuw PW, Birkenhäger WH. Alpha-adrenergic blockade and essential hypertension. In: Vanhoutte PM, Leusen J, eds.Vasodilatation. New York: Raven Press, 1981;451–458.
Moyer JH, Caplowitz C. The clinical results of oral and parenteral administration of 2-(N'p-tolyl-N'm-hydroxy-phenylamino-methyl) imidazoline hydrochloride (regitine) in the treatment of hypertension and an evaluation of the cerebral hemodynamic effects.Am Heart J 1953; 45:602–610.
Richards DA, Woodings EP, Prichard BNC. Circulatory and alpha-adrenoceptor blocking effects of phentolamine.Br J Clin Pharmacol 1978; 5:507–513.
Birkenhäger WH, de Leeuw PW. Opening remarks: Mis-match of essential hypertension's pathophysiology and current antihypertensive drugs: A perspective for alpha-one adrenergic blockade.Am Heart J 1983; 106:1235–1236.
Brogden, RN, Heel RC, Speight TM, Avery GS. Prazosin: A review of its pharmacological properties and therapeutic efficiency in hypertension.Drugs 1977; 14:163–171.
Oates HF, Graham RM, Stokes GS. Mechanism of the hypotensive action of prazosin.Arch Int Pharmacodyn Ther 1977; 227:41–48.
Rougier M, Lahon MFS, Clini AR. Prazosin—a new antihypertensive agent.Br J Clin Pract 1974; 28:280–284.
Cambridge D, Davey MJ, Massingham R. Prazosin: A selective antagonist of postsynaptic alpha adrenoceptors.Br J Pharmacol 1977; 59:514–519.
Chrysant SG. Autonomic, systemic, and renal hemodynamic actions of trimazosin in hypertensive patients.Am Heart J 1983; 106:1243–1249.
Chrysant SG, Miller RF, Brown JL, Danisa K. Long-term hemodynamic and metabolic effects of trimazosin in essential hypertension.Clin Pharmacol Ther 1981; 30:600–606.
Reid JL, Meredith PA, Elliott HL. Pharmacokinetics and pharmacodynamics of trimazosin in man.Am Heart J 1983; 106:1222–1228.
Vlachakis ND, Mendlowitz M, De Guzman D. Treatment of essential hypertension with trimazosin, a new vasodilator agent.Curr Ther Res 1975; 17:564–569.
von Kalken CK, von der Meulen J, Oe PL, et al. Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension.Eur J Clin Pharmacol 1986; 31:63–68.
Aronow WS, Tobis J, Hughes P, et al. Comparison of trimazosin and methyldopa in hypertension.Clin Pharmacol Ther 1977; 22:425–429.
De Guia D, Mendlowitz M, Russo C, et al. The effect of trimazosin in essential hypertension.Curr Ther Res 1973; 15:339–348.
Pool PE, Seagren SC, Solel AF. Clinical hemodynamic profile of trimazosin in hypertension.Am Heart J 1983; 106:1237–1242.
Taylor CR, Leader JP, Singleton W, et al. Profile of trimazosin: An effective and safe antihypertensive agent.Am Heart J 1983; 106:1269–1281.
Doxey JC, Smith CFC, Walker JM. Selectivity of blocking agents for pre- and postsynaptic alpha-adrenoceptors.Br J Pharmacol 1978; 60:91–96.
Buyniscki JP, Pircio AW, Schurig JE, Campbell JA. Effects of tiodarosin, prazosin, trimazosin and phentolamine on blood pressure, heart rate and on pre- and postsynaptic-adrenergic receptors in the rat.Clin Exp Hypertens 1980; 2:1039–1048.
Constantine JW, Lebel W, Weeks R. The hypotensive effect of trimazosin is not caused solely by alpha-one-adrenoceptor blockade.J Cardiovasc Pharmacol 1984; 5:142–150.
de Leeuw PW, Wester A, Stiensra R, et al. Hemodynamic and endocrinological studies with prazosin in essential hypertension. In: Lund-Johansen P, Mason DT, eds.Recent Advances in Hypertension and Congestive Heart Failure—Prazosin. Amsterdam: Excerpta Medica, 198;11–20.
Falch DK, Paulsen AQ, Odegaard AE, Norman N. Central and renal circulation, renin and aldosteronne in plasma during prazosin treatment in essential hypertension.Acta Med Scand 1979; 206:489–494.
Awan NA, Hermanovich FJ, Whitcomb C, et al. Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure.Am J Cardiol 1979; 44:126–131.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sampieri, L., Cuspidi, C., Boselli, L. et al. Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha1-adrenergic receptor antagonist, trimazosin, in hypertension. Cardiovasc Drug Ther 1, 535–542 (1988). https://doi.org/10.1007/BF02125737
Issue Date:
DOI: https://doi.org/10.1007/BF02125737